info@seagull-health.com
SeagullHealth
语言:
search
new
Indications for Seladelpar
501
Article source: Seagull Pharmacy
Oct 09, 2025

Seladelpar is a new-type therapeutic drug for primary biliary cholangitis (PBC), which exerts its effects by activating peroxisome proliferator-activated receptor delta (PPARδ).

Indications for Seladelpar

Main Therapeutic Uses

Seladelpar is approved for the treatment of two categories of adult patients with primary biliary cholangitis (PBC) as follows.

Combination therapy: Used in combination with ursodeoxycholic acid (UDCA), it is indicated for PBC patients with an inadequate response to UDCA.

Monotherapy: Used as monotherapy for PBC patients who cannot tolerate UDCA.

Usage Restrictions and Precautions

It is not recommended for patients with decompensated cirrhosis (e.g., ascites, variceal bleeding, hepatic encephalopathy).

It must be used under the guidance of a physician with experience in PBC treatment.

Regular monitoring of liver function indicators and bone health status is required.

Specifications and Properties of Seladelpar

Preparation Specifications

Seladelpar is an oral hard capsule preparation.

Specification: 10 mg per capsule (calculated as seladelpar free acid).

Appearance Characteristics

The capsules are opaque.

Size: Size 1 capsules.

Color: Opaque light gray capsule body and opaque dark blue capsule cap.

Marking: The capsule cap is printed with "CBAY", and the capsule body is printed with "10".

Composition

Active ingredient: 14.1 mg seladelpar lysine salt (equivalent to 10 mg seladelpar free acid).

Excipients: Butylated hydroxytoluene (BHT), colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, mannitol, microcrystalline cellulose.

Capsule shell: Gelatin, titanium dioxide, iron oxide colorants, and FD&C Blue No. 2.

Storage Method for Seladelpar

Storage Condition Requirements

Temperature: Store at room temperature between 20°C and 25°C (68°F and 77°F).

Allowable fluctuation range: Short-term exposure to temperatures between 15°C and 30°C (59°F and 86°F) is tolerable.

Precautions: Keep in the original packaging to protect from light and avoid humid environments.

Special Handling Requirements

Child protection: Packaged with child-resistant caps; store out of the reach of children.

Moisture and damage prevention: Keep the desiccant inside the bottle intact and avoid crushing or deforming the capsules.

Expired disposal: Expired drugs should be disposed of professionally in accordance with local regulations.

Note: For internal discussion among medical personnel only. For specific medication, please consult the attending physician. Drug information may change over time. For the latest information, we recommend adding a medical consultant or consulting for free online.
Recommended Articles
How to Use Seladelpar
Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-δ agonist, which was approved in the United States in 2024 for the treatment of primary biliary cholangitis (PBC).How to Use Seladelpa...
Precautions for Seladelpar Administration
Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-δ agonist. It is indicated for combination therapy with ursodeoxycholic acid (UDCA) in adult patients who have an inadequate response ...
What Are the Side Effects of Seladelpar?
Seladelpar is a peroxisome proliferator-activated receptor (PPAR)-δ agonist, primarily used for the treatment of adult patients with primary biliary cholangitis (PBC) who have an inadequate response t...
Indications for Losartan Potassium and Hydrochlorothiazide Tablets (Hyzaar)
Losartan Potassium and Hydrochlorothiazide Tablets (Hyzaar) is a compound antihypertensive medication composed of losartan potassium (an angiotensin II receptor blocker, ARB) and hydrochlorothiazide (...
How to Purchase Seladelpar
Seladelpar is a novel PPAR-δ agonist, indicated for the treatment of adult patients with primary biliary cholangitis (PBC) who have an inadequate response to ursodeoxycholic acid (UDCA) or cannot tole...
What Are the Side Effects of Opdualag?
Opdualag is a fixed-dose combination medication consisting of nivolumab and relatlimab-rmbw. It is indicated for the treatment of patients aged 12 years and older with unresectable or metastatic melan...
Precautions for Opdualag Administration
Opdualag is a fixed-dose combination preparation of nivolumab and relatlimab-rmbw, indicated for the treatment of patients aged 12 years and older with unresectable or metastatic melanoma.Precautions ...
How to Use Opdualag
Opdualag is a fixed-dose combination preparation composed of nivolumab and relatlimab-rmbw. It is indicated for the treatment of patients aged 12 years and older with unresectable or metastatic melano...
Related Articles
Dosage and Administration, Recommended Dosage of Capmatinib (Tabrecta)
Capmatinib (Tabrecta) is a highly selective MET inhibitor, offering a precision treatment option for patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutation...
What Are the Indications for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a targeted therapy medication that plays an important role in the treatment of non-small cell lung cancer associated with specific gene mutations. As a MET kinase inhibitor, i...
What Are the Purchase Channels for Capmatinib (Tabrecta)?
Capmatinib (Tabrecta) is a highly selective MET inhibitor that has demonstrated significant efficacy in patients with metastatic non-small cell lung cancer (NSCLC) harboring MET exon 14 skipping mutat...
Adverse Reactions of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is an isocitrate dehydrogenase 1 (IDH1) inhibitor, primarily indicated for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and cholangiocarcinoma...
What Are the Precautions for Using Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is a targeted therapy medication primarily indicated for the treatment of patients with malignant hematologic diseases harboring specific gene mutations.What Are the Precautions f...
Dosage and Administration, Recommended Dosage of Ivosidenib (Tibsovo)
Ivosidenib (Tibsovo) is a targeted isocitrate dehydrogenase 1 (IDH1) inhibitor that demonstrates significant value in the treatment of malignant tumors with specific gene mutations.Dosage and Administ...
What Are the Indications for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an oral isocitrate dehydrogenase-1 (IDH1) inhibitor indicated for patients with various malignant tumors harboring specific IDH1 gene mutations. By inhibiting the activity of m...
What Are the Purchase Channels for Ivosidenib (Tibsovo)?
Ivosidenib (Tibsovo) is an important targeted therapy drug against IDH1 mutations, demonstrating significant efficacy in diseases such as acute myeloid leukemia and cholangiocarcinoma. For patients in...
New Drugs
Infigratinib(Truseltiq)
Infigratinib(Truseltiq)
Treatment of previously treated, unresectable locally advanced or metastatic...
Opicapone(Ongentys)
Opicapone(Ongentys)
Adjunctive treatment to levodopa/carbidopa for reducing "off" episodes in...
Deflazacort(Emflaza)
Deflazacort(Emflaza)
Treatment of Duchenne muscular dystrophy (DMD) in patients aged 2 years and...
Faricimab-svoa(Vabysmo)
Faricimab-svoa(Vabysmo)
Treatment of neovascular age-related macular degeneration, diabetic macular...
Counselling Service
Global Drug Search
Clinical Research Recruitment
Overseas Medical Treatment
Remote Consultations
Note: Our medical consultant will contact you as soon as possible. We promise to strictly protect your privacy.
Submit
Business
  • Core products
  • Antitumor drugs
  • General drug
  • Antiviral drugs
  • Biological agents
Contact Us 
  • mailbox:info@lucius.la
Welcome to consult
ucius Pharmaceuticals (Lao) Co.,Ltd All rights reserved